Imagion Biosystems Limited is pleased to share news of research published by collaborators from the University of Sydney demonstrating that Imagion’s iron oxide nanoparticles enable low-field magnetic resonance imaging, which could provide a significant advancement in medical imaging by reducing the cost and improving the accessibility of MRI. This research reinforces the significance of the clinical and commercial opportunity for Imagion’s nanoparticles.
The Stock Network Interview – Making the business case for MagSense® cancer imaging
Izaac Ronay from The Stock Network sat down with Imagion Biosystems’ Ward Detwiler to discuss the new written series, “10 Things to Know About MagSense®”, which
